AMGEN Presents New Sotorasib Plus Chemotherapy Data in First-Line KRAS G12C NSCLC at WCLC

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

AMGEN Presents New Sotorasib Plus Chemotherapy Data in First-Line KRAS G12C NSCLC at WCLC

header-info

Sep, 13, 2023

Researchers presented data from the CODEBREAK 101 clinical trial which indicated that first-line administration of sotorasib with carboplatin and pemetrexed among adult patients with KRAS G12C-mutated advanced non-small cell lung cancer led to an ORR rate of 65% and a DCR of 100%.

Access the full article to read more here.